These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 18048949)

  • 1. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
    Jasińska M; Owczarek J; Orszulak-Michalak D
    Pharmacol Rep; 2007; 59(5):483-99. PubMed ID: 18048949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of statins: new therapeutic targets in drug design.
    Bedi O; Dhawan V; Sharma PL; Kumar P
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):695-712. PubMed ID: 27146293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins: potential new indications in inflammatory conditions.
    Endres M
    Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
    Marzilli M
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
    Takemoto M; Liao JK
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1712-9. PubMed ID: 11701455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.
    Wang CY; Liu PY; Liao JK
    Trends Mol Med; 2008 Jan; 14(1):37-44. PubMed ID: 18068482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.
    Liao JK
    Am J Cardiol; 2005 Sep; 96(5A):24F-33F. PubMed ID: 16126020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
    Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
    Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic vascular protective effects of statins in perioperative medicine.
    Fang SY; Roan JN; Luo CY; Tsai YC; Lam CF
    Acta Anaesthesiol Taiwan; 2013 Sep; 51(3):120-6. PubMed ID: 24148741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond lipid lowering: the role of statins in vascular protection.
    Liao JK
    Int J Cardiol; 2002 Nov; 86(1):5-18. PubMed ID: 12243846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
    Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
    Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular mechanisms of statins: an update on pleiotropic effects.
    Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M
    Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy.
    Tamargo J; Caballero R; Gómez R; Núñez L; Vaquero M; Delpón E
    Pharmacol Ther; 2007 Apr; 114(1):107-26. PubMed ID: 17287023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.